Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$2.29M-31.19%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph C. Sardano
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 60
- Beta
- 1.14
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 7.11
Financials
Revenue
$2.29M-31.2%Net Income
$-8.75MEBITDA
$-3.09M-5741.9%Free Cash Flow
$-3.13MEPS (diluted)
$-0.53Shares Outstanding (diluted)
16.46M+24.4%Operating Expenses
$3.95MCash & Debt
$15.19MReturn of Capital
$0.00Revenue by Segment (annual)
$27.48MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $27.48M | $-7.72M | $-0.47 |
| 2024 | $41.81M | $6.65M | $0.41 |
| 2023 | $24.41M | $485.0K | $0.03 |
| 2022 | $44.53M | $24.24M | $1.47 |
| 2021 | $27.04M | $4.12M | $0.25 |
| 2020 | $9.58M | $-6.84M | $-0.42 |
| 2019 | $27.26M | $-1.70M | $-0.07 |
| 2018 | $26.43M | $-2.02M | $-0.14 |
| 2017 | $20.59M | $-3.71M | $-0.28 |
| 2016 | $14.81M | $-346.4K | $-0.03 |
| 2015 | $10.27M | $-237.3K | $-0.02 |
| 2014 | $5.81M | $-3.70M | $-0.37 |
| 2013 | $10.48M | $107.6K | $-0.04 |
Valuation
SRTShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
107Social Signal Score
Mentions (3)
- Newsmarketbeat.com·53d ago·Neutral
Sensus Healthcare Q2 Earnings Call Highlights Sensus Healthcare NASDAQ: SRTS reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsbusinesswire.com·53d ago·Neutral
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease …
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.06 per share
Typical surprise -245.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.53 vs $-0.13miss
- Thu, May 7$-0.16 vs $-0.13miss
- Thu, Feb 12$-0.19 vs $-0.06miss
- Thu, Nov 6$-0.06 vs $-0.11beat
- Thu, Aug 7$-0.06 vs $0.01miss
- Thu, May 15$-0.16 vs $0.04miss
Estimates and results for SRTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SRTS officers and directors.
- Bought
- $985k
- Sold
- $4.7m
32 trades
28 trades
- Sachetta Ericbought
- Sachetta Ericbought
- Sachetta Ericbought
- Sachetta Ericbought
- Sachetta Ericbought
- Sachetta Ericbought
- Sardano Joseph Cbought
- Sachetta Ericbought
40 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SRTS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.